- Home
- STK vs GERN Comparison
STK vs GERN Comparison
Compare STK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STK | GERN |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 694.8M | 1.1B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | STK | GERN |
|---|---|---|
| Price | $38.60 | $1.59 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 48.8K | ★ 17.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.05 | $1.04 |
| 52 Week High | $41.46 | $2.01 |
Technical Indicators
Market Signals| Indicator | STK | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 50.12 |
| Support Level | $38.25 | $1.20 |
| Resistance Level | $39.97 | $1.68 |
| Average True Range (ATR) | 1.06 | 0.14 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 12.81 | 34.21 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.